While Sandoz has emerged as the front-runner to get a generic version of GlaxoSmithKline’s respiratory blockbuster Advair to the US market, rival Hikma has not given up despite a major setback.

UK-listed Hikma Pharma has filed a response to the FDA that it hopes will clear the way for approval of its generic of GlaxoSmithKline’s blockbuster respiratory drug Advair. Hikma has been ...

The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug, Victoza, clearing the way for the launch of another copy of the ...

Hikma recently received the Food and Drug Administration’s permission for a new generic, and the company also launched two new generic products. The FDA approved Hikma's first generic ...

Hikma will continue producing its 8 mg naloxone HCl nasal spray in its Columbus, Ohio manufacturing facility and will provide it to Emergent as its exclusive commercial partner. "We are thrilled ...

London – M42, a global health leader powered by artificial intelligence (AI), and Hikma Pharmaceuticals PLC (Hikma), announced the signing of a strategic memorandum of understanding (MOU), to ...